The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 5, 2003, Pages 623-642

  Pelengaris, Stella ^a   Khan, Mike ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Antisense; Apoptosis; c Myc; Cancer; Cell cycle; Diabetes

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; IMMUNOSUPPRESSIVE AGENT; MYC PROTEIN; PROTEIN BCL 2; RAPAMYCIN; RAS PROTEIN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC HEART DISEASE; MOUSE; NEUROECTODERM TUMOR; NONHUMAN; PANCREAS ISLET CELL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN TARGETING; RESTENOSIS; REVIEW; TRANSGENIC MOUSE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CORONARY RESTENOSIS; DIABETES MELLITUS; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, MYC; GLUCOSE; GROWTH SUBSTANCES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR ESCAPE;

EID: 0141996279     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.5.623     Document Type: Review

References (159)

1. VENNSTROM B, SHEINESS D, ZABIELSKI J, BISHOP JM: Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J. Virol (1982) 42:773-779.
2. SPENCER CA, GROUDINE M: Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res. (1991) 56:1-48.
3. DANG CV: c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. (1999) 19:1-11.
4. NESBIT CE, TERSAK JM, PROCHOWNIK EV: Myc oncogenes and human neoplastic disease. Oncogene (1999) 18:3004-3016.
5. SCHLAGBAUER-WADL H, GRIFFIOEN M, VAN ELSAS A et al.: Influence of increased c-Myc expression on the growth characteristics of human melanoma. J. Invest. Dermatol. (1999) 112:332-336.
6. HENRIKSSON M, LUSCHER B: Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res. (1996) 68:109-182.
7. O'CONNELL BC, CHEUNG AF, SIMKEVICH CP et al.: A large scale genetic analysis of c-Myc-regulated gene expression patterns. J. Biol. Chem. (2003) 278(14):12563-12573.
8. PELENGARIS S, KHAN M, EVAN GI: Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell (2002) 109(3):321-334.
9. PELENGARIS S, LITTLEWOOD TD, KHAN M, ELIA G, EVAN G: Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell. (1999) 3(5):565-577.
10. BAEK SH, KIOUSSI C, BRIATA P et al.: Regulated subset of G1 growth-control genes in response to derepression by the Wnt pathway. Proc. Natl. Acad. Sci. USA (2003) 100(6):3245-3250.
11. SASAKI T, SUZUKI H, YAGI K et al.: Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor β-induced repression of c-myc. Cancer Res. (2003) 63(4):801-806.
12. RAMSEY R, BARTON A, GONDA T: Targeting c-Myb expression in human disease. Expert Opin. Ther. Targets (2003) 7(2):235-248.
13. TWORKOWSKI KA, SALGHETTI SE, TANSEY WP: Stable and unstable pools of Myc protein exist in human cells. Oncogene (2002) 21(55):8515-8520.
14. BLACKWOOD EM, EISENMAN RN: Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science (1991) 251(4998):1211-1217.
15. AMATI B, BROOKS MW, LEVY N, LITTLEWOOD TD, EVAN GI, LAND H: Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell(1993) 72(2):233-245.
16. SAKAMURO D, PRENDERGAST GC: New Myc-interacting proteins: a second Myc network emerges. Oncogene (1999) 18(19):2942-2954.
17. AMATI B, ALEVIZOPOULOS K, VLACH J: Myc and the cell cycle. Front. Biosci. (1998) 3:D250-D268.
18. EILERS M: Control of cell proliferation by Myc family genes. Mol. Cell (1999) 9(1):1-6.
19. AMATI B: Integrating Myc and TGF-β signalling in cell-cycle control. Nat. Cell Biol. (2001) 3(5):E112-E113.
20. DAVIS AC, WIMS M, SPOTTS GD, HANN SR, BRADLEY A: A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev. (1993) 7(4):671-682.
21. SCHMID P, SCHULZ WA, HAMEISTER H: Dynamic expression pattern of the myc protooncogene in midgestation mouse embryos. Science (1989) 243(4888):226-229.
22. HIRVONEN H, MAKELA TP, SANDBERG M, KALIMO H, VUORIO E, ALITALO K: Expression of the myc proto-oncogenes in developing human fetal brain. Oncogene (1990) 5(12):1787-1797.
23. MATEYAK MK, OBAYA AJ, ADACHI S, SEDIVY JM: Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. (1997) 8(10):1039-1048.
24. SCHORL C, SEDIVY JM: Loss of protooncogene c-Myc function impedes G(1) phase progression both before and after the restriction point. Mol. Biol. Cell (2003) 14(3):823-835.
25. ROSENWALD IB, RHOADS DB, CALLANAN LD, ISSELBACHER KJ, SCHMIDT EV: Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 α in response to growth induction by c-myc. Proc. Natl. Acad. Sci. USA (1993) 90(13):6175-6178.
26. JONES RM, BRANDA J, JOHNSTON KA et al.: An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol. Cell. Biol. (1996) 16(9):4754-4764.
27. COLLER HA, GRANDORI C, TAMAYO P et al.: Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. USA (2000) 97(7):3260-3265.
28. JOHNSTON LA, PROBER DA, EDGAR BA, EISENMAN RN, GALLANT P: Drosophila myc regulates cellular growth during development. Cell (1999) 98(6):779-790.
29. IRITANI BM, EISENMAN RN: c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc. Natl. Acad. Sci. USA (1999) 96(23):13180-13185.
30. SCHUHMACHER M, STAEGE MS, PAJIC A et al.: Control of cell growth by c-Myc in the absence of cell division. Curr. Biol. (1999) 9(21):1255-1258.
31. BEIER R, BURGIN A, KIERMAIER A et al.: Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events. EMBO J. (2000) 19(21):5813-5823.
32. GOMEZ-ROMAN N, GRANDORI C, EISENMAN RN, WHITE RJ: Direct activation of RNA polymerase III transcription by c-Myc. Nature (2003) 421(6920):290-294.
33. STEINER P, PHILIPP A, LUKAS J et al.: Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J. (1995) 14(19):4814-4826.
34. BERNS K, HIJMANS EM, BERNARDS R: Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene (1997) (11):1347-1356.
35. BOUCHARD C, THIEKE K, MAIER A et al.: Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. (1999) 18(19):5321-5333.
36. HERMEKING H, RAGO C, SCHUHMACHER M et al.: Identification of CDK4 as a target of c-MYC. Proc. Natl. Acad. Sci. USA (2000) 97(5):2229-2234.
37. O'HAGAN RC, OHH M, DAVID G et al.: Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev. (2000) 14(17):2185-2191.
38. PEREZ-ROGER I, KIM SH, GRIFFITHS B, SEWING A, LAND H: Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1)and p21(Cip1). EMBO J. (1999) 18(19):5310-5320.
39. MULLER D, BOUCHARD C, RUDOLPH B et al.: Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene (1997) 15(21):2561-2576.
40. STALLER R, PEUKERT K, KIERMAIER A et al.: Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell Biol. (2001) 3(4):392-399.
41. HEROLD S, WANZEL M, BEUGER V et al.: Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol. Cell (2002). In Press.
42. MCMAHON SB, VAN BUSKIRK HA, DUGAN KA, COPELAND TD, COLE MD: The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell (1998) 94(3):363-374.
43. MCMAHON SB, WOOD MA, COLE MD: The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol. Cell. Biol. (2000) 20(2):556-562.
44. AMATI B, FRANK SR, DONJERKOVIC D, TAUBERT S: Function of the c-Myc oncoprotein in chromatin remodeling and transcription. Biochim Biopbys. Acta (2001) 1471(3):M135-M145.
45. BOUCHARD C, DITTRICH O, KIERMAIER A et al.: Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev. (2001) 15(16):2042-2047.
46. FRANK SR, SCHROEDER M, FERNANDEZ P, TAUBERT S, AMATI B: Binding of c-Myc to chromatin mediates mitogen-induced acerylation of histone H4 and gene activation. Genes Dev. (2001) 15(16):2069-2082.
47. EBERHARDY SR, D'CUNHA. CA, FARNHAM PJ: Direct examination of histone acetylation on Myc target genes using chromatin immunoprecipitation. J. Biol. Chem. (2000) 275:33798-33805.
48. LA ROCCA SA, CROUCH DH, GILLESPIE DA: c-Myc inhibits myogenic differentiation and myoD expression by a mechanism which can be dissociated from cell transformation. Oncogene (1994) 9(12):3499-3508.
49. RYAN KM, BIRNIE GD: Cell-cycle progression is not essential for c-Myc to block differentiation. Oncogene (1997) 14(23):2835-2843.
50. GRANDORI C, COWLEY SM, JAMES LP, EISENMAN RN: The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. (2000) 16:653-699.
51. FOLEY KP, EISENMAN RN: Two MAD tails: what the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network. Biochim. Biophys. Acta (1999) 1423(3):M37-M47.
52. DEAN M, LEVINE RA, CAMPISI J: c-myc regulation during retinoic acid-induced differentiation of F9 cells is posttranscriptional and associated with growth arrest. Mol. Cell. Biol. (1986) 6(2):518-524.
53. DOTTO GP, GILMAN MZ, MARUYAMA M, WEINBERG RA: c-myc and c-fos expression in differentiating mouse primary keratinocytes. EMBO J. (1986) 5(11):2853-2857.
54. LEMAITRE JM, BUCKLE RS, MECHALI M: c-Myc in the control of cell proliferation and embryonic development. Adv. Cancer Res. (1996) 70:95-144.
55. CHIN L, SCHREIBER-AGUS N, PELLICER I et al.: Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. Proc. Natl. Acad. Sci. USA (1995) 92(18):8488-8492.
56. HURLIN PJ, FOLEY KP, AYER DE, EISENMAN RN, HANAHAN D, ARBEIT JM: Regulation of Myc and Mad during epidermal differentiation and HPV-associated rumorigenesis. Oncogene(1995) 11(12):2487-2501.
57. HURLIN PJ, QUEVA C, KOSKINEN PJ et al.: Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc-dependent transformation and are expressed during neural and epidermal differentiation. EMBO J. (1995) 14(22):5646-5659.
58. GANDARILLAS A, WATT FM: c-Myc promotes differentiation of human epidermal stem cells. Genes Dev. (1997) 11(21):2869-2882.
59. ARNOLD I, WATT FM: c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr. Biol. (2001) 11(8):558-568.
60. IRITANI BM, EISENMAN RN: c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc. Natl. Acad. Sci. USA (1999) 96(23):13180-13185.
61. AYER DE, LAWRENCE QA, EISENMAN RN: Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell (1995) 80(5):767-776.
62. SCHREIBER-AGUS N, CHIN L, CHEN K et al.: An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell (1995) 80(5):777-786.
63. JAMES L, EISENMAN RN: Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo. Proc. Natl. Acad. Sci. USA (2002) 99(16):10429-10434.
64. EVAN GI, WYLLIE AH, GILBERT CS et al.: Induction of apoptosis in fibroblasts by c-myc protein. Cell (1992) 69(1):119-128.
65. ASKEW DS, ASHMUN RA, SIMMONS BC, CLEVELAND JL: Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene (1991) 6(10):1915-1922.
66. DEBBAS M, WHITE E: Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. (1993) 7(4):546-554.
67. QIN XQ, LIVINGSTON DM, KAELIN WG Jr, ADAMS PD: Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA (1994) 91(23):10918-10922.
68. SHAN B, LEE WH: Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell. Biol. (1994) 14(12):8166-8173.
69. WU X, LEVINE AJ: p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA (1994) 91(9):3602-3606.
70. STRASSER A, HARRIS AW, BATH ML, CORY S: Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature (1990) 348(6299):331-333.
71. ADAMS JM, HARRIS AW, PINKERT CA et al.: The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (1985) 318(6046):533-538.
72. BLYTH K, TERRY A, O'HARA M et al.: Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene (1995) 10(9):1717-1723.
73. ELSON A, DENG C, CAMPOS-TORRES J, DONEHOWER LA, LEDER P: The MMTV/c-myc: transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene (1995) 11(1):181-190.
74. JACOBS JJ, SCHEIJEN B, VONCKEN JW, KIEBOOM K, BERNS A, VAN LOHUIZEN M: Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. (1999) 13(20):2678-2690.
75. EISCHEN CM, WEBER JD, ROUSSEL MF, SHERR CJ, CLEVELAND JL: Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. (1999) 13(20):2658-2669.
76. TANAKA H, MATSUMURA I, EZOE S et al.: E2F1 and c-Myc potentiate apoptosis through inhibition of NF-κB activity that facilitates MnSOD-mediated ROS elimination. Mol. Cell (2002) 9(5):1017-1029.
77. VAFA O, WADE M, KERN S et al.: c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell (2002) 9(5):1031-1044.
78. HUEBER AO, ZORNIG M, LYON D, SUDA T, NAGATA S, EVAN GI: Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science (1997) 278(5341):1305-1309.
79. KLEFSTROM J, VASTRIK I, SAKSELA E, VALLE J, EILERS M, ALITALO K: c-Myc induces cellular susceptibility to the cytotoxic action of TNF-α. EMBO J. (1994) 13(22):5442-5450.
80. LUTZ W, FULDA S, JEREMIAS I, DEBATIN KM, SCHWAB M: MycN and IFNγ cooperate in apoptosis of human neuroblastoma cells. Oncogene (1998) 17(3):339-346.
81. JUIN P, HUEBER AO, LITTLEWOOD T, EVAN G: c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. (1999) 13(11):1367-1381.
82. ACEHAN D, JIANG X, MORGAN DG, HEUSER JE, WANG X, AKEY CW: Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol. Cell (2002) 9(2):423-432.
83. MARTINOU JC, GREEN DR. Breaking the mitochondrial barrier. Nat. Rev. Mol. Cell. Biol. (2001) 2(1):63-67.
84. SOUCIE EL, ANNIS MG, SEDIVY J et al.: Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. Mol. Cell. Biol. (2001) 21(14):4725-4736.
85. JUIN P, HUNT A, LITTLEWOOD T et al.: c-Myc functionally cooperates with Bax to induce apoptosis. Mol. Cell. Biol. (2002) 22(17):6158-6169.
86. MORRISH F, GIEDT C, HOCKENBERY D: c-MYC apoptotic function is mediated by NRF-1 target genes. Genes Dev. (2003) 17(2):240-255.
87. GROSS A, JOCKEL J, WEI MC, KORSMEYER SJ: Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. (1998) 17(14):3878-3885.
88. KHALED AR, KIM K, HOFMEISTER R, MUEGGE K, DURUM SK: Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. Proc. Natl. Acad. Sci. USA (1999) 96(25):14476-14481.
89. ESKES R, DESAGHER S, ANTONSSON B, MARTINOU JC: Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol. Cell. Biol. (2000) 20(3):929-935.
90. BRENNER C, CADIOU H, VIEIRA HL et al.: Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene (2000) 19(3):329-336.
91. 2+ ions. J. Cell Biol. (1998) 143(1):217-224.
92. GREEN DR, EVAN GI: A matter of life and death. Cancer Cell (2002) 1(1):19-30.
93. DESBIENS KM, DESCHESNES RG, LABRIE MM et al.: c-Myc potentiates the mitochondrial pathway of apoptosis by acting upstream of Ask1 in the p38 signaling cascade. Biochem. J. (2003) 372(2):631-641.
94. IONOV Y, YAMAMOTO H, KRAJEWSKI S, REED JC, PERUCHO M: Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc. Natl. Acad. Sci. USA (2000) 97(20):10872-10877.
95. KAUFFMANN-ZEH A, RODRIGUEZ-VICIANA P, ULRICH E et al.: Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature (1997) 385(6616):544-548.
96. ZHA J, HARADA H, YANG E, JOCKEL J, KORSMEYER SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell (1996) 87(4):619-628.
97. ZINDY F, EISCHEN CM, RANDLE DH et al.: Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. (1998) 12(15):2424-2433.
98. OTSUKI Y, TANAKA M, KAMO T, KITANAKA C, KUCHINO Y, SUGIMURA H: Guanine nucleotide exchange factor, Tiam 1, directly binds to c-Myc and interferes with c-Myc-mediated apoptosis in Rat-1 fibroblasts. J. Biol. Chem. (2003) 278(7):5132-5140.
99. KOHL NE, RULEY HE: Role of c-myc in the transformation of REF52 cells by viral and cellular oncogenes. Oncogene(1987) 2(1):4148.
100. MOUGNEAU E, LEMIEUX L, RASSOULZADEGAN M, CUZIN F: Biological activities of v-myc and rearranged c-myc oncogenes in rat fibroblast cells in culture. Proc. Natl. Acad. Sci. USA (1984) 81(18):5758-5762.
101. LAND H, PARADA LF, WEINBERG RA: Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature (1983) 304(5927):596-602.
102. LAND H, CHEN AC, MORGENSTERN JP, PARADA LF, WEINBERG RA: Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol. Cell. Biol. (1986) 6(6):1917-1925.
103. LUGO TG, WITTE ON: The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol. Cell. Biol. (1989) 9(3):1263-1270.
104. FANIDI A, HARRINGTON EA, EVAN GI: Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature (1992) 359(6395):554-556.
105. REED JC, CUDDY M, HALDAR S et al.: BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc. Natl. Acad. Sci. USA (1990) 87(10):3660-3664.
106. MORGENBESSER SD, DEPINHO RA: Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer. Semin. Cancer Biol. (1994) 5(1):21-36.
107. PELENGARIS S, KHAN M, EVAN G: c-Myc: more than just a matter of life and death. Nat. Rev. Cancer (2002) 2:764-776.
108. LITTLEWOOD TD, HANCOCK DC, DANIELIAN PS, PARKER MG, EVAN GI: A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. (1995) 23(10):1686-1690.
109. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86(3):353-364.
110. JANZ A, SEVIGNANI C, KENYON K, NGO CV, THOMAS-TIKHONENKO A: Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. Nucleic Acids Res. (2000) 28(11):2268-2275.
111. NGO CV, GEE M, AKHTAR N et al.: An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. Cell Growth Differ. (2000) 11(4):201-210.
112. BRANDVOLD KA, NEIMAN P, RUDDELL A: Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene (2000) 19(23):2780-2785.
113. OKAJIMA E, THORGEIRSSON UP: Different regulation of vascular endothelial growth factor expression by the ERK and p38 kinase pathways in v-ras, v-raf, and v-myc transformed cells. Biochem. Biophys. Res. Commun. (2000) 270(1):108-111.
114. CHRISTOFORI G, NAIK P. HANAHAN D: A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature (1994) 369(6479):414-418.
115. FELSHER DW, BISHOP JM: Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell (1999) 4(2):199-207.
116. D'CRUZ CM, GUNTHER EJ, BOXER RB et al.: c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med. (2001) 7(2):235-239.
117. WU Y, RENARD CA, APIOU F et al.: Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors. Oncogene (2002) 21(10):1518-1526.
118. FELSHER DW, BISHOP JM: Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. USA (1999) 96(7):3940-3944.
119. FEST T, MOUGEY V, DALSTEIN V et al.: c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis. Oncogene (2002) 21(19):2981-2990.
120. JAIN M, ARVANITIS C, CHU K et al.: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 297(5578):102-104.
121. OSTER SK, HO CS, SOUCIE EL, PENN LZ: The myc oncogene: marvelouslY complex. Adv. Cancer Res. (2002) 84:81-154.
122. BERNASCONI NL, WORMHOUDT TA, LAIRD-OFFRINGA IA: Post-transcriptional deregulation of myc genes in lung cancer cell lines. Am. J. Respir. Cell Mol. Biol. (2000) 23(4):560-565.
123. CHAPPELL SA, LEQUESNE JP, PAULIN FE et al.: A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation. Oncogene (2000) 19(38):4437-4440.
124. BARONE MV, COURTNEIDGE SA: Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src. Nature (1995) 378(6556):509-512.
125. BOWMAN T, BROOME MA, SINIBALDI D et al.: Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA (2001) 98(13):7319-7324.
126. CHIARIELLO M, MARINISSEN MJ, GUTKIND JS: Regulation of c-myc expression by PDGF through Rho GTPases. Nat. Cell Biol. (2001) 3(6):580-586.
127. KOLLIGS FT, KOLLIGS B, HAJRA KM et al.: γ-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of β-catenin. Genes Dev. (2000) 14(11):1319-1331.
128. HUANG H, COLELLA S, KURRER M, YONEKAWA Y, KLEIHUES P, OHGAKI H: Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res. (2000) 60(24):6868-6874.
129. WATATANI M, INUI H, NAGAYAMA K et al.: Identification of high-risk breast cancer patients from genetic changes of their tumors. Surg. Today (2000) 30(6):516-522.
130. GREGORY MA, HANN SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol. Cell. Biol. (2000) 20(7):2423-2435.
131. SALGHETTI SE, KIM SY, TANSEY WP: Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMB0 J. (1999) 18(3):717-726.
132. SEARS R, NUCKOLLS F, HAURA E, TAYA Y, TAMAI K, NEVINS JR: Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. (2000) 14(19):2501-2514.
133. HAHN WC, WEINBERG RA: Modelling the molecular circuitry of cancer. Nat. Rev. Cancer (2002) 2(5):331-341.
134. BUTLER AE, JANSON J, BONNER-WEIR S, RITZEL R, RIZZA RA, BUTLER PC: β-cell deficit and increased β-cell apoptosis in humans with Type 2 diabetes. Diabetes (2003) 52(1):102-110.
135. POITOUT V, ROBERTSON RP: Minireview: secondary β-cell failure in Type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology (2002) 143(2):339-342.
136. BONNER-WEIR S: Islet growth and development in the adult. J. Mol. Endocrinol. (2000) 24:297-302.
137. JONAS JC, SHARMA A, HASENKAMP W et al.: Chronic hyperglycaemia triggers loss of pancreatic β-cell differentiation in an animal model of diabetes. J. Biol. Chem. (1999) 20:14112-14121.
138. LAYBUTT DR, GLANDT M, XU G et al.: Critical reduction in β-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes. J. Biol. Chem. (2003) 278(5):2997-3005.
139. LAYBUTT DR, WEIR GC, KANETO H et al.: Overexpression of c-Myc in β-cells of transgenic mice causes proliferation and apoptosis, downregulation of insulin gene expression, and diabetes. Diabetes (2002) 51(6):1793-1804.
140. WATSON JD, OSTER SK, SHAGO M, KHOSRAVI F, PENN LZ: Identifying genes regulated in a Myc-dependent manner. J. Biol. Chem. (2002) 277:36921-36930.
141. SCHUHMACHER M, KOHLHUBER F, HOLZEL M et al.: The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. (2001) 29:397-406.
142. O'HAGAN RC, SCHREIBER-AGUS N, CHEN K et al.: Gene-target recognition among members of the myc superfamily and implications for oncogenesis. Nat. Genet. (2000) 24:113-119.
143. NEIMAN PE, RUDDELL A, JASONI C et al.: Analysis of gene expression during myc oncogene-induced lymphomagenesis in the bursa of Fabricius. Proc. Natl. Acad. Sci. USA (2001) 98:6378-6383.
144. WANG H, PRASAD G, BUOLAMWINI JK, ZHANG R. Antisense anticancer oligonucleotide therapeutics. Curr. Cancer Drug Targets (2001) 1(3):177-196.
145. WATSON PH, PON RT, SHIU RP: Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res. (1991) 51(15):3996-4000.
146. WHITESELL L, ROSOLEN A, NECKERS LM: In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide. Antisense Res. Dev. (1991) 1(4):343-350.
147. KNAPP DC, MATA JE, REDDY MT, DEVI GR, IVERSEN PL: Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Anticancer Drugs (2003) 14(1):39-47.
148. FATTORI R, PIVA T: Drug-eluting stents in vascular intervention. Lancet (2003) 361(9353):247-249.
149. KIPSHIDZE NN, KIM HS, IVERSEN P et al.: Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J. Am. Coll. Cardiol. (2002) 39(10):1686-1691.
150. KUTRYK MJ, FOLEY DP, VAN DEN BRAND M et al.: ITALICS trial local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J. Am. Coll. Cardiol. (2002) 39(2):281-287.
151. TSUNEOKA M, KODA Y, SOEJIMA M, TEYE K, KIMURA H: A novel myc target gene, mina53, that is involved in cell proliferation. J. Biol. Chem. (2002) 277(38):35450-35459.
152. GRAND CL, HAN H, MUNOZ RM et al.: The cationic porphyrin TMPyP4 downregulates c-MYC and human telomerase reverse transcriptase expression and inhibits rumor growth in vivo. Mol. Cancer Ther. (2003) 2(2):208.
153. WILSON AJ, VELCICH A, ARANGO D et al.: Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. (2002) 62(21):6006-6010.
154. COLLIER JJ, DOAN TT, DANIELS MC, SCHURR JR, KOLLS JK, SCOTT DK: c-Myc is required for the glucose-mediated induction of metabolic enzyme genes. J. Biol. Chem. (2003) 278(8):6588-6595.
155. EWALD D, LI M, EFRAT S et al.: Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science (1996) 273(5280):1384-1386.
156. CHIN L, TAM A, POMERANTZ J et al.: Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 400(6743):468-472.
157. HUETTNER CS, ZHANG P, VAN ETTEN RA, TENEN DG: Reversibility of acute β-cell leukaemia induced by BCR-ABL1. Nat. Genet. (2000) 24(1):57-60.
158. JACKSON EL, WILLIS N, MERCER K et al.: Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. (2001) 15(24):3243-3248.
159. FISHER GH, WELLEN SL, KLIMSTRA D et al.: Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. (2001) 15(24):3249-3262.